Annual Report 2008 (In Swedish)
Lund, April 15, 2009Hansa Medical AB (publ)For more information, please contact:Emanuel Björne, CEOMobile: +46 (0)70 717 54 77E-mail: email@example.comHansa Medical is a preclinical and early clinical biopharmaceutical development company focused on inflammation. The company develops three primary products, IdeS, anti-alpha-11 and HMD-301. IdeS is a novel treatment prior to organ transplantation. Anti-alpha-11 is a novel and more specific rheumatoid arthritis treatment. HMD-301 is a novel diagnostic method for diagnosis and prognosis of severe sepsis. Hansa Medical is publicly traded at NASDAQ OMX First North under ticker symbol HMED.